Welcome to our dedicated page for Adc Therapeutics Sa news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics Sa stock.
ADC Therapeutics SA reports news on its commercial-stage oncology business focused on antibody-drug conjugates. The company markets ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC with FDA accelerated approval and European Commission conditional approval for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
Recurring updates cover ZYNLONTA product revenue, manufacturing and commercialization activity, clinical development in combination regimens and earlier lines of therapy, including LOTIS program studies, and corporate financing matters. Company news also includes quarterly financial results, investor presentations, conference participation and equity inducement grants under its compensation plans.
ADC Therapeutics (NYSE: ADCT) announced positive results from the initial safety run-in of the LOTIS-5 Phase 3 trial, showing a 75% overall response rate and a 40% complete response rate for ZYNLONTA in combination with rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma. The results will be presented at the SOHO 2022 conference in Houston, Texas from September 28-October 1, 2022. Additionally, the company plans to showcase pivotal Phase 2 data for Camidanlumab Tesirine (Cami) during the event.
ADC Therapeutics (NYSE: ADCT) and Swedish Orphan Biovitrum AB announce a positive opinion from the CHMP of the European Medicines Agency, recommending ZYNLONTA® (loncastuximab tesirine) for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This opinion is now under review by the European Commission, with a decision expected in 4Q 2022. Earlier, ADC Therapeutics secured an exclusive licensing deal with Sobi for ZYNLONTA's development in Europe. The favorable CHMP opinion reflects progress towards broader patient access in Europe.
ADC Therapeutics (NYSE: ADCT) announced that Ameet Mallik, CEO, will participate in a fireside chat at Morgan Stanley’s 20th Annual Global Healthcare Conference on September 13, 2022, at 11:45 a.m. ET. A live webcast will be available on the Investors section of the company’s website, with a replay accessible for 30 days.
ADC Therapeutics is focused on developing innovative antibody drug conjugates to treat cancer, including ZYNLONTA, which targets relapsed or refractory diffuse large B-cell lymphoma.
ADC Therapeutics (NYSE: ADCT) announced a series of strategic transactions, including a new $175 million senior secured term loan with Owl Rock and Oaktree Capital Management. The company settled $115 million of convertible notes with Deerfield Management, in which Deerfield took equity as part of the settlement. An additional investment of $6.25 million for common shares was made by Owl Rock. The new debt facility, maturing in 2029, helps maintain liquidity into early 2025, supporting the advancement of ADC Therapeutics' cancer treatments.
ADC Therapeutics reported financial results for the second quarter of 2022, highlighting net sales for ZYNLONTA® at $17.3 million, up from $3.8 million year-over-year. The company established a license agreement with Sobi® to enhance global access to ZYNLONTA, extending its cash runway to early 2025. Notable advancements include the initiation of multiple clinical trials, including LOTIS-9 and LOTIS-7. Net loss for the quarter was $64.4 million, showing an improvement compared to the previous year. ADC's focus on increasing product awareness is expected to support ongoing growth.
ADC Therapeutics (NYSE: ADCT) announced a conference call and webcast scheduled for August 9, 2022, at 8:30 a.m. ET to disclose its Q2 2022 financial results and share business updates. The call will provide investors with insights into the company’s performance and operations. ADC Therapeutics specializes in targeted antibody drug conjugates for cancer treatment, including the FDA-approved ZYNLONTA for diffuse large B-cell lymphoma, and ongoing developments in its ADC pipeline.
ADC Therapeutics announced the initiation of a Phase 1b clinical trial for ADCT-601 (mipasetamab uzoptirine), targeting AXL in patients with advanced solid tumors. The trial aims to assess ADCT-601's safety as a standalone and in combination with gemcitabine, particularly in sarcoma, a tumor resistant to current treatments. ADCT-601 has shown a manageable tolerability profile and promising preclinical synergy with gemcitabine. This advancement continues ADC Therapeutics' focus on improving cancer treatment through targeted antibody-drug conjugates.
ADC Therapeutics has initiated the LOTIS-9 Phase 2 clinical trial, targeting unfit and frail patients with previously untreated DLBCL. This trial aims to evaluate the efficacy and tolerability of ZYNLONTA (loncastuximab tesirine-lpyl) combined with rituximab in approximately 80 patients aged 80 and older. The trial follows promising results from the LOTIS-5 Phase 3 trial, addressing a significant medical need in a typically underserved population. The study may pave the way for new treatment options for these patients.
Overland ADCT BioPharma has initiated its Phase 3 LOTIS-5 trial in China, dosing the first patient with ZYNLONTA® combined with rituximab for DLBCL. This follows ZYNLONTA's accelerated FDA approval as a single-agent therapy for relapsed DLBCL. The trial aims to support a supplemental BLA in the U.S. and China for transplant-ineligible patients. This significant milestone reflects the commitment to advancing treatment options for patients with difficult-to-treat DLBCL in China.
Summary not available.